Furmonertinib rechallenge for first-line third-generation EGFR TKI-resistant EGFR-mutant NSCLC: A retrospective propensity score-matched cohort study
{{output}}
Background: Overcoming resistance of first-line third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer (NSCLC) remained a challenge. This study aimed to compare t... ...
